Buy an Access Pass now and secure your opportunity to upgrade to future technology at a discounted price.†
Those who purchase a new pump from Medtronic will now have the option to also purchase an Access Pass for about $2 per month.‡ The pass can be redeemed for a 50% discount off of a future in-warranty upgrade.
The Access Pass allows you to upgrade while in-warranty at a discounted price, as long as there is more than six months remaining on your pump warranty. The in-warranty upgrade program price fluctuates over time, but when you purchase an Access Pass today, you will secure a discount for the future.
Here is an example of the potential savings that can result from an Access Pass. In this example the in-warranty upgrade cost, also known as the Pathway price, is $799*.
(Example does not include applicable sales tax or other fees)
|Future Upgrade with Purchase of Access Pass||Future Upgrade without an Access Pass|
|Cost of Access Pass||$99‡||$0|
|Cost to Upgrade||$799 x 50% = $399||$799|
That's a savings of more than $300!
Our newest technology, the MiniMed™ 670G system, was the first self-adjusting insulin delivery system available1. More than 70,000 people in the U.S. are using the MiniMed™ 670G system, the most advanced hybrid closed loop technology available today. 3 Medtronic continues investing in bringing new products to market on our path to enhancing options for diabetes therapy. We hope to launch multiple innovations in the future. By purchasing an Access Pass, you’ll secure an opportunity to move to the newest technology at a discounted price.
For $99 or about $2 per month ‡, an Access Pass can be added on to the purchase of both the MiniMed™ 670G system and the MiniMed™ 630G system.
An insulin pump combined with a CGM can enable your pump to automatically1 adjust your basal (background) insulin every five minutes based on your CGM readings2.
Just like how a thermostat adjusts to keep the temperature at a desired level, the MiniMed™ 670G system adapts to your unique insulin needs. It monitors your glucose levels day and night and self-adjusts background insulin based on your real-time needs.
The MiniMed™ 670G system helps stabilize glucose levels with fewer highs and lows, so you can focus less on your diabetes and more on whatever the day brings.
The MiniMed™ 630G insulin pump mimics some of the functions of a healthy pancreas. When combined with our CGM, it takes action for you with the SmartGuard™ Suspend on low feature - providing advanced diabetes control that can help keep your glucose levels in range and stable4.
The price to upgrade while in-warranty can change based on a variety of factors. The Access Pass guarantees you a 50% discount off the future Pathway price. Using an Access Pass could save you hundreds of dollars compared to upgrading only using the Pathway program.
Check out our current Pathway program offer.
Access to Local Trainers
Unlike most companies, we’ve invested in growing our nationwide training team. That means your initial product training will be handled by your local representative who can meet with you in-person.
Commitment to Innovation
We have a track record of innovation. We were the first company to develop a sensor-integrated insulin pump, as well as being the first company to launch an automated insulin delivery system. We will continue to invest in products that transform diabetes care and improve clinical outcomes.
Support Throughout Your Journey
We care about your continued success on insulin pump therapy. We have hundreds of service team members that are dedicated to helping ensure your therapy stays on track.
Ease of Billing
As the only company that sells every component of our insulin pump system, you’ll only make purchases through us, saving you time that’s typically spent managing your therapy-related finances.
† See program terms and conditions for more details.
‡ The total cost of the Access Pass is $99. The cost may be added to the Flex payment plan. Calculation of the total monthly payment will be determined at time of purchase. The payment will include an additional $6/month fee. Access Pass alone may not be set up on a payment plan.
* $799 price is not guaranteed at time of use. Pathway price could be lower or higher depending on when Access Pass is redeemed.
1. Refers to Auto Mode. Individual results may vary. Some interaction required.
2. Based on sensor glucose.
3.Data from voluntary CareLink™ Personal uploads on file.
4. Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med.2010;363:311– 320.
The Medtronic MiniMed™ 670G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of type 1 diabetes mellitus in persons, seven years of age and older, requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed™ 670G system includes SmartGuard™ technology, which can be programmed to automatically adjust delivery of basal insulin based on continuous glucose monitor sensor glucose values, and can suspend delivery of insulin when the sensor glucose value falls below or is predicted to fall below predefined threshold values. The system requires a prescription. The Guardian Sensor (3) glucose values are not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. A confirmatory finger stick test via the CONTOUR®NEXT LINK 2.4 blood glucose meter is required prior to making adjustments to diabetes therapy. All therapy adjustments should be based on measurements obtained using the CONTOUR®NEXT LINK 2.4 blood glucose meter and not on values provided by the Guardian Sensor (3). Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the CONTOUR®NEXT LINK 2.4 blood glucose meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an alternative site (palm) or from a control solution test. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise. If a control solution test is out of range, please note that the result may be transmitted to your pump when in the “Always” send mode.
WARNING: Medtronic performed an evaluation of the MiniMed™ 670G system and determined that it may not be safe for use in children under the age of 7 because of the way that the system is designed and the daily insulin requirements. Therefore this device should not be used in anyone under the age of 7 years old. This device should also not be used in patients who require less than a total daily insulin dose of 8 units per day because the device requires a minimum of 8 units per day to operate safely.
Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. The safety of the MiniMed™ 670G system has not been studied in pregnant women. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult http://www.medtronicdiabetes.com/important-safety-information#minimed-670g and the appropriate user guide at http://www.medtronicdiabetes.com/download-library.Important Safety Information: MiniMed™ 630G System
Indicated for the continuous delivery of insulin, at set and variable rates, for the management of diabetes mellitus. MiniMed™ 630G system is approved for ages 14 years or older with Guardian™ Sensor 3 and MiniMed™ 630G system is approved for ages 16 years or older with Enlite™ sensor. Both systems require a prescription. Insulin infusion pumps and associated components of insulin infusion systems are limited to sale by or on the order of a physician and should only be used under the direction of a healthcare professional familiar with the risks of insulin pump therapy. Pump therapy is not recommended for people who are unwilling or unable to perform a minimum of four blood glucose tests per day. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Insulin pumps use rapid-acting insulin. If your insulin delivery is interrupted for any reason, you must be prepared to replace the missed insulin immediately. Replace the infusion set every 48–72 hours, or more frequently per your healthcare professional’s instructions. Insertion of a glucose sensor may cause bleeding or irritation at the insertion site. Consult a physician immediately if you experience significant pain or if you suspect that the site is infected. The information provided by CGM systems is intended to supplement, not replace, blood glucose information obtained using a blood glucose meter. A confirmatory fingerstick using a CONTOUR® NEXT LINK 2.4 meter is required prior to making adjustments to diabetes therapy. Always check the pump display when using a CONTOUR® NEXT LINK 2.4 meter, to ensure the glucose result shown agrees with the glucose results shown on the meter. Do not calibrate your CGM device or calculate a bolus using a result taken from an Alternative Site (palm) or a result from a control solution test. If a control solution test is out of range, please note that the result may be transmitted to your pump when in the “Always” send mode. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise. The MiniMed™ 630G system is not intended to be used directly for preventing or treating hypoglycemia but to suspend insulin delivery when the user is unable to respond to the Suspend on low alarm and take measures to prevent or treat hypoglycemia themselves. Therapy to prevent or treat hypoglycemia should be administered according to the recommendations of the user’s healthcare provider.
WARNING: The SmartGuard™ Suspend on low feature will cause the pump to temporarily suspend insulin delivery for two hours when the sensor glucose reaches a set threshold. Under some conditions of use the pump can suspend again, resulting in very limited insulin delivery. Prolonged suspension can increase the risk of serious hyperglycemia, ketosis, and ketoacidosis. Before using the SmartGuard feature, it is important to read the SmartGuard™ feature information in the User Guide and discuss proper use of the feature with your healthcare provider.See www.medtronicdiabetes.com/importantsafetyinformation and the appropriate user guides for additional important details.
Ascensia, the Ascensia Diabetes Care logo, and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care.